Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
This heightened sensitivity may represent an early or mild form of the same process that produces full allodynia at higher intensities
Neuropsychopharmacology 39, 22332243
Other Key Findings Metabolic improvements: Participants saw reductions in A1C (for those with prediabetes or diabetes), fasting glucose, and triglycerides Liver fat reduction: Retatrutide reduced liver fat by up to 50%, which is why Eli Lilly added a NASH-specific trial to the Phase 3 program Side effects: Mostly gastrointestinal (nausea, diarrhea, constipation), similar to other GLP-1 drugs but manageable with slow titration Discontinuation rate: About 10% of participants stopped due to side effects, comparable to tirzepatide and semaglutide Study limitation: The Phase 2 trial was only 48 weeks long
Tirzepatide represents the next generation of incretin therapy with potentially even greater efficacy, and retatrutide may push the boundaries further still
(2005) Anatomy and regulation of the central melanocortin system Nature Neuroscience, 8(5):571-578
